Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT Data

  • 📰 Medscape
  • ⏱ Reading Time:
  • 85 sec. here
  • 26 min. at publisher
  • 📊 Quality Score:
  • News: 117%
  • Publisher: 55%

Obesity News

Obese,Weight Loss,Weight Management

Semaglutide remains effective for weight loss at 4 years in people with preexisting cardiovascular disease and overweight/obesity but without T2D and provides CV benefits regardless of weight.

VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide leads to clinically significant and durable weight loss as well as improvements in waist circumference and waist circumference-to-height ratio , in patients with preexisting cardiovascular disease , overweight or obesity, and without diabetes.

"Here we see that an obesity medication can reduce heart attack, stroke, and heart disease death in individuals with obesity who had had a prior heart attack, stroke, or peripheral artery disease but who did not have diabetes and the reduction was meaningful — by 20%," she emphasized. Markers of obesity including body composition and fat distribution : -11.1% vs -7.5% with< .0001."We think this is due to greater exposure to drug levels. There was also an effect across age, but it was not clinically significant. Everyone was getting some effect of weight loss."

Overall, adverse events were fewer in those patients treated with semaglutide compared with placebo, and this was primarily driven by reduction in cardiovascular events, reported Ryan."Individuals across all baseline levels of BMI had the same response."Deanfield reported on the relationship between weight measures at baseline as well as weight change after early treatment and CV outcomes.

"This suggests alternative mechanisms of improved CV outcomes with semaglutide beyond reduction in adiposity," remarked Deanfield."Many patients with overweight and obesity and not just those who lose weight, may receive CV benefit from semaglutide." Naveed Sattar, PhD, professor of metabolic medicine at the University of Glasgow, Scotland, commented on the results, reflecting on CV benefits and weight loss, and pointing out that they,"suggest the direct effect of semaglutide on the heart and blood vessels may be most responsible for its benefits on MACE but they cannot discount an additive benefit, even if small, of the weight loss on benefits seen.

Source: Healthcare Press (healthcarepress.net)

Obese Weight Loss Weight Management CV Risk Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors Cardiovascular Risk Management Body Mass Index BMI Heart Failure Heart Blood Blood Vessels Cardiovascular Disease Cvd - Cardiovascular Disease Stroke Cerebrovascular Accident CVA - Cerebrovascular Accident UK Site Content United Kingdom Site Content United Kingdom UK

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Beyond Weight Loss: Semaglutide Delivers Major Heart Health BenefitsScience, Space and Technology News 2024
Source: SciTechDaily1 - 🏆 84. / 68 Read more »

Weight Loss Maintained With Slow Taper of SemaglutideA digital lifestyle program used in combination with semaglutide from low starting dose shows participants can maintain weight loss after tapering and stopping the drug, irrespective of starting BMI.
Source: Medscape - 🏆 386. / 55 Read more »

Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: Forbes - 🏆 394. / 53 Read more »

Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: ForbesTech - 🏆 318. / 59 Read more »

Semaglutide, gastric bypass delay weight loss plateau, study findsChloe Nordquist is a national journalist for the E.W. Scripps Company. She has a passion for telling community stories and giving a voice to the voiceless. Chloe has had the opportunity to report across the world, as far as Milan and Berlin. Previously she worked at news stations in California’s Central Valley and Southwest Florida.
Source: 10News - 🏆 732. / 50 Read more »

Mango Benefits: Dietitian On Gut Health, Weight Loss, VitaminsA. Pawlowski is a TODAY health reporter focusing on health news and features. Previously, she was a writer, producer and editor at CNN.
Source: TODAYshow - 🏆 389. / 55 Read more »